Taiho Oncology Announces Decitabine and Cedazuridine to be Included in NIH Precision ...
Taiho Oncology, Inc., a company developing and commercializing novel treatments for hematologic malignancies and solid tumors ...
Bio-Path Holdings, Inc.: Bio-Path Holdings Provides 2025 Clinical and Operational Update
Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Hold ...
Bio-Path Holdings Provides 2025 Clinical and Operational Update
Advancing Multiple Programs in Areas of Significant Unmet Medical NeedSeveral Milestones Across Clinical Development Pipeline Expected in ...